- Home
- HIX vs MRK Comparison
HIX vs MRK Comparison
Compare HIX & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIX | MRK |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.5M | 268.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HIX | MRK |
|---|---|---|
| Price | $4.25 | $121.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $121.00 |
| AVG Volume (30 Days) | 449.5K | ★ 14.2M |
| Earning Date | 01-01-0001 | 02-03-2026 |
| Dividend Yield | ★ 13.14% | 2.85% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | N/A | ★ 7.28 |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | N/A | $5.02 |
| Revenue Next Year | N/A | $5.31 |
| P/E Ratio | ★ N/A | $16.38 |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $4.16 | $73.31 |
| 52 Week High | $5.08 | $122.66 |
Technical Indicators
Market Signals| Indicator | HIX | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 71.39 |
| Support Level | $4.22 | $116.10 |
| Resistance Level | $4.28 | $122.46 |
| Average True Range (ATR) | 0.03 | 3.23 |
| MACD | 0.00 | 0.58 |
| Stochastic Oscillator | 73.04 | 97.40 |
Price Performance
Historical ComparisonAbout HIX Western Asset High Income Fund II Inc.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its investment objective is to maximize current income by investing at least 80% of its net assets and borrowings for investment purposes in high-yield debt securities.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).